Cost-effectiveness of preimplantation genetic testing for aneuploidies
Objective: To evaluate the economical benefit of preimplantation genetic testing of aneuploidies (PGT-A) when applied in an extended culture and stringent elective single ET framework. Design: Theoretical cost-effectiveness study. Setting: Not applicable. Patients/Animal(s): None. Intervention(s): C...
| Autores: | , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2019 |
| País: | España |
| Recursos: | INCLIVA |
| Repositório: | r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| OAI Identifier: | oai:incliva.fundanetsuite.com:p3731 |
| Acesso em linha: | https://incliva.portalinvestigacion.com/publicaciones/3731 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Preimplantation genetic testing elective single embryo transfer effectiveness blastocyst |
| Resumo: | Objective: To evaluate the economical benefit of preimplantation genetic testing of aneuploidies (PGT-A) when applied in an extended culture and stringent elective single ET framework. Design: Theoretical cost-effectiveness study. Setting: Not applicable. Patients/Animal(s): None. Intervention(s): Comparison of the cost-effectiveness between two IVF treatment strategies: serial transfer of all available blastocysts without genetic testing (first fresh transfer and subsequent frozen-thawed transfer); and systematic use of genetic testing (trophectoderm biopsy, freeze-all, and frozen-thawed transfers of euploid blastocysts). The costs considered for this analysis are based on regional public health system provider. Main Outcome Measure(s): Costs per live birth. Result(s): Cost-effectiveness profile of PGT-A improves with female age and number of available blastocysts. Sensitivity analyses varying the costs of ET, the costs of genetic analyses, the magnitude of the detrimental impact of PGT-A on live birth rate, and the crude live birth rates change to some extent the thresholds for effectiveness but generally confirm the notion that PGT-A can be economically advantageous in some specific subgroups. Conclusion(s): PGT-A can be cost-effective in specific clinical settings and population groups. Economic considerations deserve attention in the debate regarding the clinical utility of PGT-A. ((C) 2019 by American Society for Reproductive Medicine.) |
|---|